Meeting
2017 ASCO Annual Meeting
Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).
Authors
David Goldstein
Prince of Wales Hospital, University of New South Wales, Cancer Survivors Centre, Sydney, Australia
David Goldstein , Daniel D. Von Hoff , E. Gabriela Chiorean , Michele Reni , Josep Tabernero , Ramesh K. Ramanathan , Abdalla Aly , Marc Botteman , Julia Wilkersen , Sandra Margunato-Debay , Brian Lu , Chrystal Ursula Louis , Markus Frederic Renschler , Desmond Micahel Thomas McGovern , Chee Khoon Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT00844649
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4109)
DOI
10.1200/JCO.2017.35.15_suppl.4109
Abstract #
4109
Poster Bd #
101
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III ΜΡΑCT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).
First Author: David Goldstein
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic factors for GEM + nab-PTX combination therapy in elderly patients with pancreatic cancer.
First Author: Kazuki Watabe
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
First Author: Esther Pijnappel